Literature DB >> 14592646

The prognostic significance of antigen expression in leukaemia.

Richard Schabath1, Richard Ratei, Wolf Dieter Ludwig.   

Abstract

Numerous immunophenotypic features have been examined for their potential prognostic significance in predicting treatment outcome in leukaemias. These include immunophenotypic subgroups of acute lymphoblastic leukaemia (ALL) and immature acute myeloid leukaemia, expression of individual surface antigens or combined immunophenotypic features, and more recently, molecules mediating the multidrug resistance phenotype or being involved in the regulation of drug-induced apoptosis. Most previous studies investigating the prognostic significance of antigen expression in leukaemia have not used the information provided by multiparameter flow cytometry and have chosen rather arbitrary cut-off points for marker positivity. Moreover, given significant associations between immunophenotypic features and genetic abnormalities in leukaemic cells, immunophenotyping as an independent predictor of treatment outcome has been questioned. Thus, except for lineage assignment of leukaemic blasts and definition of maturational status in ALL, information provided by immunophenotyping is currently not applied to risk-classification systems or used for planning patient treatment in leukaemia. We review some of the recent findings regarding the prognostic impact of distinct immunophenotypic features in acute leukaemias and myelodysplastic syndrome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14592646     DOI: 10.1016/s1521-6926(03)00087-2

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  8 in total

1.  Interleukin-3 receptor α chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy.

Authors:  Wen Du; Juan Li; Wei Liu; Yanli He; Junxia Yao; Yu Liu; Jun Lin; Jine Zheng
Journal:  Tumour Biol       Date:  2015-10-16

2.  Regulation of Src family kinases involved in T cell receptor signaling by protein-tyrosine phosphatase CD148.

Authors:  Ondrej Stepanek; Tomas Kalina; Peter Draber; Tereza Skopcova; Karel Svojgr; Pavla Angelisova; Vaclav Horejsi; Arthur Weiss; Tomas Brdicka
Journal:  J Biol Chem       Date:  2011-05-04       Impact factor: 5.157

3.  The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia.

Authors:  Ana Paula Alegretti; Christina Matzenbacher Bittar; Rosane Bittencourt; Amanda Kirchner Piccoli; Laiana Schneider; Lúcia Mariano Silla; Suzane Dal Bó; Ricardo Machado Xavier
Journal:  Rev Bras Hematol Hemoter       Date:  2011

4.  Chromosome abnormalities in T-cell acute lymphoblastic leukemia in Korea.

Authors:  Joonhong Park; Myungshin Kim; Hae Kyung Lee; Yonggoo Kim; Kyungja Han; Jungok Son; Seok Lee; Nack-Gyun Chung; Bin Cho
Journal:  Int J Hematol       Date:  2014-01-29       Impact factor: 2.490

5.  Individualized leukemia cell-population profiles in common B-cell acute lymphoblastic leukemia patients.

Authors:  Jian-Hua Yu; Jing-Tao Dong; Yong-Qian Jia; Neng-Gang Jiang; Ting-Ting Zeng; Hong Xu; Xian-Ming Mo; Wen-Tong Meng
Journal:  Chin J Cancer       Date:  2012-07-02

6.  Serum Survivin and TP53 Gene Expression in Children with Acute Lymphoblastic Leukemia.

Authors:  Raida S Yahya; Manal I Fouda; Hatim A El-Baz; Tamer E Mosa; Mohamed D Abd Elmaksoud
Journal:  Iran J Public Health       Date:  2012-01-31       Impact factor: 1.429

7.  Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis.

Authors:  Chien-Yuan Chen; Wen-Chien Chou; Woei Tsay; Jih-Luh Tang; Ming Yao; Sheng-Yi Huang; Hwei-Fang Tien
Journal:  BMC Cancer       Date:  2013-03-08       Impact factor: 4.430

Review 8.  The functional role of microRNA in acute lymphoblastic leukemia: relevance for diagnosis, differential diagnosis, prognosis, and therapy.

Authors:  Chengxin Luan; Zixue Yang; Baoan Chen
Journal:  Onco Targets Ther       Date:  2015-10-13       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.